TG Therapeutics Inc (TGTX)

Cash ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Cash and cash equivalents US$ in thousands 179,894 195,822 82,910 75,477 92,933 150,902 97,009 61,469 102,304 109,860 147,073 185,676 298,887 326,512 401,707 471,514 553,439 254,154 260,512 52,051
Short-term investments US$ in thousands 131,106 145,219 134,342 134,308 124,575 78,257 47,896 78,241 59,374 66,082 48,636 47,525 15,876 30,338 41,752 52,334 51,987 46 15,058 26,284
Total current liabilities US$ in thousands 90,679 125,114 108,664 99,684 53,720 57,678 72,667 63,076 53,201 36,447 43,326 54,656 65,384 87,655 87,551 92,494 87,554 77,670 67,537 63,118
Cash ratio 3.43 2.73 2.00 2.10 4.05 3.97 1.99 2.21 3.04 4.83 4.52 4.27 4.81 4.07 5.07 5.66 6.91 3.27 4.08 1.24

December 31, 2024 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($179,894K + $131,106K) ÷ $90,679K
= 3.43

The cash ratio of TG Therapeutics Inc provides insight into the company's ability to cover its short-term obligations with its available cash and cash equivalents. A higher cash ratio indicates a stronger liquidity position and financial health.

Examining the data provided, we observe fluctuations in TG Therapeutics Inc's cash ratio over the quarters from March 31, 2020, to December 31, 2024. The cash ratio ranged from a low of 1.24 on March 31, 2020, to a high of 6.91 on December 31, 2020, indicating significant variability in the company's ability to cover its short-term obligations solely with cash.

Throughout the following quarters, the cash ratio generally remained above 4, signaling an adequate level of liquidity for TG Therapeutics Inc's short-term needs. However, there were occasional decreases in the cash ratio, such as the decline to 2.10 on March 31, 2024, which may merit further investigation into potential changes in the company's cash position or working capital management.

Overall, the cash ratio data suggests that TG Therapeutics Inc has maintained a reasonable level of liquidity over the analyzed periods, with the potential need to monitor any significant fluctuations to ensure the company's ability to meet its short-term obligations efficiently.